Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Short-term Investments (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Short-term Investments for 5 consecutive years, with $59.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 59441.0% year-over-year to $59.5 million, compared with a TTM value of $59.5 million through Dec 2025, up 59441.0%, and an annual FY2025 reading of $59.5 million, up 59441.0% over the prior year.
  • Short-term Investments was $59.5 million for Q4 2025 at Aligos Therapeutics, up from $57.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $104.3 million in Q2 2025 and bottomed at $21000.0 in Q2 2022.
  • Average Short-term Investments over 5 years is $17.8 million, with a median of $204500.0 recorded in 2021.
  • The sharpest move saw Short-term Investments tumbled 99.87% in 2023, then soared 117657.14% in 2024.
  • Year by year, Short-term Investments stood at $164000.0 in 2021, then dropped by 29.88% to $115000.0 in 2022, then fell by 13.04% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then surged by 59441.0% to $59.5 million in 2025.
  • Business Quant data shows Short-term Investments for ALGS at $59.5 million in Q4 2025, $57.2 million in Q3 2025, and $104.3 million in Q2 2025.